Skip to main content
. Author manuscript; available in PMC: 2011 Dec 21.
Published in final edited form as: Front Biosci (Schol Ed). 2011 Jan 1;3:788–796. doi: 10.2741/s187

Figure 1.

Figure 1

Schematic representation of the current understanding of ILK1 signaling crosstalk with pathways that are commonly deregulated in hormonal cancers. Crosstalk of ILK axis with the estrogen receptor, ERBB2, Pak1 signaling pathways suggest that deregulation of ILK expression and/or function is likely to contribute to the hormonal cancer progression and development of therapy resistance.